Source: https://www.federalregister.gov/documents/2007/08/21/E7-16400/government-owned-inventions-availability-for-licensing
Timestamp: 2017-10-20 15:07:14
Document Index: 401693220

Matched Legal Cases: ['Application No. 60', 'Application No. 60', 'Application No. 60', 'Application No. 60', 'Application No. 60', 'Application No. 60']

72 FR 46641
E7-16400
Prophylactic Vaccines and Therapeutic Monoclonal Antibodies Against Influenza
Antiviral Compounds With Broad Neutralization Capabilities
Design of Multi-Functional RNA Nanoparticles and Nanotubes
https://www.federalregister.gov/d/E7-16400 https://www.federalregister.gov/d/E7-16400
Description of Technology: This technology describes development of H5N1 influenza vaccine candidates in which mutations have been introduced to increase affinity of the hemagglutinin (HA) for the sialic acid receptor found in humans, which have a different sialic acid linkage than the corresponding avian receptor. These mutations could therefore result in a higher immune response in vaccines, producing a more robust response than other H5N1 vaccine candidates that retain their avian receptor preferences. These mutations also changed antibody-sensitivity of the vaccine candidates. The H5 modifications can be expressed from DNA or adenoviral vectors, or the proteins themselves can be administered. Additionally, these mutated HAs can be used to develop therapeutic monoclonal antibodies. The technology describes three (3) unique monoclonal antibodies that react with wild-type H5, wild-type H5 and mutant HA equivalently, and the mutant HA, respectively.
Applications: Prophylactic influenza vaccine; Therapeutic antibodies.
Inventors: Gary J. Nabel et al. (VRC/NIAID).
Patent Status: U.S. Patent Application No. 60/850,761 filed 10 Oct 2006 (HHS Reference No. E-306-2006/0-US-01).
U.S. Patent Application No. 60/860,301 filed 20 Nov 2006 (HHS Reference No. E-306-2006/1-US-01).
U.S. Patent Application No. 60/920,874 filed 30 Mar 2007 (HHS Reference No. E-306-2006/2-US-01).
U.S. Patent Application No. 60/921,669 filed 02 Apr 2007 (HHS Reference No. E-306-2006/3-US-01).
Description of Technology: The NIH is pleased to announce as available for licensing a technology that provides for novel antiviral compounds effective against a broad spectrum of viruses. The compounds utilize soluble phospholipases, exemplified by PLA2-X and others, either alone or as a fusion protein with a viral binding polypeptide. These compositions are able to inactivate viruses through enzymatic degradation of the viral membrane without affecting target cells Start Printed Page 46642of infection. The potential broad application of these compounds could address a significant health need for effective antivirals.
Applications: This technology provides compositions and methods for the treatment of viral infection and has human and veterinary applications.
Advantages: The compounds described by the current technology are not necessarily specific for a type of virus or viral strain like many currently available antiviral compounds, and therefore have broad therapeutic antiviral applications. Further, virions resistant to damage by antibody and complement have been shown to be lysed by compounds of the invention suggesting antiviral surveillance independent of a humoral immune response.
Development Status: Proof of concept in vitro studies using human cells have shown antiviral activity with viruses pseudotyped with envelope proteins from Ebola, HIV, Marburg and MoMuLV.
Inventors: Gary Nabel and Jae-Ouk Kim (VRC/NIAID).
Publication: J-O Kim et al. Lysis of human immunodeficiency virus type 1 by a specific secreted human phospholipase A2. J Virol. 2007 Feb;81(3):1444-1450.
Patent Status: PCT Application No. PCT/US2007/004471 filed 21 Feb 2007 (HHS Reference No. E-013-2006/1-PCT-01).
Licensing Contact: Susan Ano, Ph.D.; 301/435-5515; AnoS@mail.nih.gov
Description of Invention: The characteristic function of nanoparticles is their ability to deliver drug across biological barriers to the target site while protecting the drugs from the biological environment until they reach the target site. The present invention provides polyvalent RNA nanostructures comprising RNA I inverse (RNA Ii) or RNA II inverse (RNA IIi) like motifs that have multiple positions available for conjugation of therapeutic, diagnostic or delivery agents. The nanoparticles of the invention do not induce significant immune response by themselves and are smaller than currently available nanoparticles and therefore allow for increased efficiency of administration. The nanoparticles of this invention have the ability to deliver one or more different therapeutic agents in a single particle. Further, the RNA nanoparticles are also capable of self-assembly into nanotubes of various shapes which offer potentially broad uses in medical implants, gene therapy, nanocircuits, scaffolds and medical testing.
1. Use as diagnostic tool.
2. Use as drug delivery composition to treat various diseases or conditions.
3. Use in screening or identifying potential chemotherapeutic agents.
4. Use in riboswitch aptamers, ribozymes or beacons.
5. Use in nanocircuits, medical implants, gene therapy, scaffolds and medical testing.
Market: Broad application in various fields, such as therapeutics, drug delivery, diagnostics, provides a wide market potential.
Inventors: Bruce A. Shapiro and Yaroslava G. Yingling (NCI).
Publication: YG Yingling and BA Shapiro. Computational Design of an RNA Hexagonal Nanoring and an RNA Nanotube. Nano Lett. 2007 Jul 6. Epub ahead of print,.doi 10.1021/nl070984r.
Patent Status: U.S. Provisional Application No. 60/810,283 filed 02 Jun 2006 (HHS Reference No. E-233-2006/0-US-01).
U.S. Provisional Application No. 60/918,181 filed 14 Mar 2007 (HHS Reference No. E-233-2006/1-US-01).
Licensing Contact: Robert M. Joynes J.D., M.S.; 301/594-6565; joynesr@mail.nih.gov.
Collaborative Research Opportunity: The National Cancer Institute's Nanobiology Program (http://www-lecb.ncifcrf.gov/​bshapiro/​index.html) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize RNA nanostructures. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.
[FR Doc. E7-16400 Filed 8-20-07; 8:45 am]